risankizumab (TBC)

Original post, click here

Generic Name: risankizumab

Brand Name: TBC

Manufacturer: AbbVie Corporation

Indications: Psoriasis, moderate to severe plaque

Manufacturer Requested Reimbursement Criteria1:

That risankizumab be reimbursed for adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Submission Type: New

Project Status: Pending

Call For Patient Input: September 19, 2018

Patient Input Closed: November 8, 2018

Anticipated Date: October 18, 2018

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback